Plain-English translation of NCT07688187 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing two companion medications called PD-32766D and PD-32766T to treat a type of advanced kidney cancer called clear cell renal cell carcinoma. PD-32766D is an imaging medication that helps doctors see if your cancer cells have a specific target called CA9, which this treatment can attack. If your cancer has this target, you may receive PD-32766T, the treatment medication, which is designed to deliver radiation directly to cancer cells.
Standard treatments for advanced kidney cancer often stop working over time, leaving patients with limited options. This trial exists to test whether this new medication pair—which combines imaging to find the right patients with targeted treatment—can help people whose cancer has become resistant to other therapies.
You likely qualify if…
You likely don't qualify if…
First, you will receive an imaging scan with the diagnostic medication (PD-32766D) to see if your cancer has the target this treatment can attack. If the scan is positive, you will then enter the treatment phase, receiving doses of the therapeutic medication (PD-32766T) according to a schedule determined by the research team. The trial has two phases: an initial dose-finding phase where doses are slowly increased to find the right amount, and then an expansion phase where more patients receive the dose that worked best. Throughout the trial, you will have regular visits for safety checks, blood tests, and imaging to see how well the treatment is working.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States